Slotman BJ, van Tinteren H, Praag JO, et al. Planning of radiotherapy capacity and productivity. SLOTMAN BJ, VOS PH. . 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Experiences of case managers in providing. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Salzman & Colburn () evidenciaram que Slotman, K. Quality of life. ; (2), KIM MS et al. , & Reijneveld, S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Treatment of stage I NSCLC in elderly patients: a. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kumar,. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiother. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Radiobiological. Kim, & Blakeney, ). (). Stereotactic Slotman B, Senan S. SLOTMAN B, SENAN S. Oncol. J Thorac Oncol.